Compositions and methods for targeting clec12a-expressing cancers
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorMarco L. Davila
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for targeted treatment of CLEC12A-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CLEC12A-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CLEC12A-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CLEC12A-expressing malignant cells.
Claims21
A chimeric antigen receptor (CAR) polypeptide, comprising a CLEC12A antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region.
A fusion polypeptide comprising the following formula:
- VLI-VHI-VLT-VHT,
- VLT-VHT-VLI-VHI,
- VHT-VLT-VHI-VLI,
- VHI-VLI-VHT-VLT,
- VLI-VHI-VHT-VLT,
- VLT-VHT-VHI-VLI,
- wherein “VLI” is a light chain variable domain specific for an immune cell antigen;
- wherein “VHT” is a heavy chain variable domain specific for CLEC12A;
- wherein “VLT” is a light chain variable domain specific for CLEC12A;
- wherein “VH” is a heavy chain variable domain specific for the immune cell antigen;
- wherein “-” consists of a peptide linker or a peptide bond.
21-23. (canceled)
Dependencies are inferred from the claim text.